BRANDY RUTLAND: Open Payments
NPI 1225628761 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$927 in 61 payments from 13 companies in 2025. Trend: 2023 $1,236 · 2024 $650 · 2025 $927
Food & beverage: $927
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $207 |
| Tris Pharma Inc | 9 | $155 |
| Axsome Therapeutics, Inc. | 13 | $144 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Supernus Pharmaceuticals, Inc. | 5 | $78 |
| ABBVIE INC. | 4 | $72 |
| Neurocrine BioSciences, Inc. | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| Corium, LLC | 2 | $26 |
Products named: FANAPT, Auvelity, Dyanavel XR, REXULTI, Qelbree, VRAYLAR, Onyda XR, INGREZZA.
Industry payments across MS — which companies pay providers there.
